key: cord-0937551-y3wws1bz
authors: Berk, Justin; Brinkley-Rubinstein, Lauren; Murphy, Matthew; Chan, Phil; Rich, Josiah
title: MAb for symptomatic COVID-19 in correctional facilities: an important opportunity
date: 2021-02-19
journal: Lancet
DOI: 10.1016/s0140-6736(21)00354-8
sha: 6b60a862d3af4267a902d5abed31821ff961d262
doc_id: 937551
cord_uid: y3wws1bz

nan

In response to the COVID-19 pandemic, as well as implementing widespread surveillance testing of residents and staff, universal mask wearing, small group cohorting, and vaccination of detained individuals at high risk, the Rhode Island Department of Corrections (RI, USA) administered an anti-SARS-CoV-2 mAb approved by the FDA and Emergency Use Authorization to a symptomatic, incarcerated person with COVID-19 on Jan 22, 2021, for the first time. The individual met criteria on the basis of timing of symptoms, age, and presence of comorbidities. There were no complications, and the individual did not require hospitalisation. To our knowledge, mAbs have been sparsely used in correctional settings across the USA. This treatment, and any other approved treatment that has the potential to reduce serious disease and death from COVID-19, should be made widely available to individuals who are incarcerated or detained and meet eligibility criteria.

Incarcerated individuals are at high risk of infection and death from COVID-19 3 and are often overlooked in this pandemic. However, they can have a major role in statewide outbreaks. 4 MAb treatments not only benefit individuals at high risk of disease but can also decrease the burden on overrun community medical centres and hospitals. In the current environment, where implementation of mAbs has proven challenging and many doses of medication go unused nationally, 5 correctional facilities offer the unique opportunity to efficiently identify and administer this evidence-based intervention.

Health departments, hospital systems, policy makers, and correctional administrations should collaborate to ensure access to evidence-based treatments, such as mAb therapy, as quickly as possible. In this way, society can not only treat a marginalised population at high risk but also efficiently decrease community burden on the local health-care infrastructure.

2 US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19

COVID-19 cases and deaths in federal and state prisons

Incarceration and its disseminations: COVID-19 pandemic lessons from Chicago's Cook County Jail

Monoclonal antibodies: overburdened hospitals are not offering this treatment against COVID-19